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Aim/Introduction: To assess the utility of 68Ga-PSMA PET / 
CT studies in the clinical practice of patients with occult 
biochemical recurrence of prostate carcinoma, with 
negative or inconclusive radiological imaging and PET / CT 
18F-Choline studies. Materials and Methods: Retrospective 
descriptive study. The first 10 patients with a history of 
prostate carcinoma, treated with curative intent and who 
had suspected biochemical recurrence with low PSA values 
(range: 0.04-2.35 ng / ml) were selected. Imaging, prostate 
ultrasound, CT, and / or pelvic MRI were negative, and all 
of them had negative or inconclusive 18F-Choline PET 
/ CT. All patients were referred for a 68Ga-PSMA PET / CT. 
Protocol: Dose 2.2MBq / Kg. 20mg of furosemide at minute 
15. Images from the skull to the proximal third to mid-
thigh at 60 min . Late images at 3 hours if needed. Results: 
In 6 of the 10 patients (60%), the 68Ga-PSMA managed to 
locate the occult biochemical recurrence, and in all of them 
there were changes in the therapeutic attitude. In 3 of the 
patients (30%) 68Ga-PSMA was negative, and the vigilant 
attitude was continued with PSA controls and imaging 
studies according to the usual protocols. These patients 
had the lowest PSA values  (less than 0.4). One of the 68Ga 
PSMA studies was inconclusive, reporting the presence of 
a dubious right iliac adenopathy. Conclusion: 68Ga-PSMA 
PET / CT allows early diagnosis, with low PSA values, of 
occult biochemical recurrence of prostate carcinoma, 
even in patients with negative 18F-choline PET / CT. The 
68Ga-PSMA findings changed the therapeutic attitude in a 
significant proportion of patients. References: Comparison 
of PET imaging with a 68Ga-labelled PSMA ligand and 
18F-choline-based PET/CT for the diagnosis of recurrent 
prostate cancerAli Afshar-Oromieh, Christian M. Zechmann, 
Anna Malcher, Matthias Eder, Michael Eisenhut, Heinz G. 
Linhart, Tim Holland-Letz, Boris A. Hadaschik, Frederik L. 
Giesel, Jürgen Debus & Uwe Haberkorn European Journal 
of Nuclear Medicine and Molecular Imaging volume 
41, pages11-20(2014)68Ga-PSMA PET/CT for restaging 
recurrent prostate cancer: which factors are associated with 
PET/CT detection rate?Francesco Ceci, Christian Uprimny, 
Bernhard Nilica, Llanos Geraldo, Dorota Kendler, Alexander 
Kroiss, Jasmin Bektic, Wolfgang Horninger, Peter Lukas, 
Clemens Decristoforo, Paolo Castellucci, Stefano Fanti & 
Irene J. VirgoliniEuropean Journal of Nuclear Medicine and 
Molecular Imaging volume 42, pages1284-1294(2015)
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Aim/Introduction: To analyze the validity of [18F]F-Choline 
PET-CT results in prostate cancer recurrence in our daily 
practice, based on theoretical cut-off points of prostate-
specific antigen (PSA), its kinetic, and PSA doubling time 
(PSADT), to identify predictors of positivity and modify the 
indication criteria. Materials and Methods: Prior to the validity 
analysis, a descriptive, prospective analysis of consecutive 
patients with prostate cancer treated with curative intent 
by radical prostatectomy (RP) or radiotherapy (RT), who 
underwent PET-CT scan with recurrence criteria: PSA ≥1 or 
PSA 0.4-1 with PSADT <6 months after RP; PSA> Nadir + 2 
after RT, was performed. Results: From April to December 
2019, 69 patients were included, 40 were treated with RP 
(58%) and 29 with RT (42%). In 45 patients (65%) PET-CT was 
able to identify recurrence of the disease (positive PET) and 
in 24 it was not (negative PET). Of patients treated with RP, 
82,5% (33/40) had PSA>1, and of those, 61% were positive 
PET. 17,5% (7/40) had PSA<1 and PSADT< 6 months (28/69), 
with positive PET in 43% of patients. 76% of patients had 
a positive PET after RT. Positive PET results were obtained 
in 57% of patients with PSADT>6months (28/69), in 71% if 
PSADT<6months (41/69) and in 81% of patients if PSADT<3 
months (16/69). After RP and RT, PET was positive in 50% 
and 62,5% of patients respectively if PSADT>6 months, in 
61% and 92% if PSADT<6 months and in 77% and 100% if 
PSADT<3 months. Conclusion: Preliminarily and awaiting 
validation, it seems that PSA>1 after RP or Nadir +2 after 
RT is an indicator of PET-CT. There seems to be a tendency 
that shows that PSA<1 after RP is an indicator of PET-CT if 
PSADT<3 months. PSADT <3 or <6 months could be the 
best predictor of positivity of PET-CT with [18F]F-Choline in 
recurrent prostate cancer. References: None
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Aim/Introduction: To analyze the PET CT findings visualized 
in studies with 18F-FCH, with tumor recurrence suspicion 
in patients treated of prostate cancer with Gleason score 
less than 7 or with a PSA value less than 2ng / mL prior to 
PET. Materials and Methods: Retrospective study was made 
from March 2016 to October 2019, including 20 patients 
(22 explorations) treated of prostate cancer (mean age 
73 years) with tumor recurrence suspicion and doubtful 
imaging tests, considering two independent samples: 
those with Gleason <7 (14 patients) and those with PSA 
<2ng / mL prior to PET (6 patients). The PET findings, the 
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